<DOC>
	<DOCNO>NCT02584816</DOCNO>
	<brief_summary>This Phase 3 , open-label , randomize study evaluate lot-to-lot consistency manufacture Bovine Rotavirus Pentavalent Vaccine ( BRV-PV ) .</brief_summary>
	<brief_title>Phase III Study Rotavirus Vaccine Evaluate Lot-to-lot Consistency Interference With Routine UIP Immunization</brief_title>
	<detailed_description>The study design evaluate lot-to-lot consistency manufacture Rotavirus vaccine test vaccine infant order demonstrate equivalence induction specific anti-rotavirus IgA antibody across three production lot . The study also examine potential interference vaccine UIP vaccine administer concurrently assess non-inferiority immune response vaccine administer / without study vaccine .</detailed_description>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy infant establish medical history clinical examination enter study . 2 . Age : 68 week time enrollment . 3 . Parental ability willingness provide write informed consent . 4 . Parent intend remain area child study period . 5 . Receipt birth dose Hepatitis B vaccine OPV . 1 . Presence diarrhea vomit previous 72 hour day enrollment ( temporary exclusion ) . 2 . Presence fever day enrollment ( temporary exclusion ) . 3 . Acute disease time enrollment ( temporary exclusion ) . 4 . Concurrent participation another clinical trial point throughout entire timeframe study . 5 . Presence significant malnutrition systemic disorder determine medical history / physical examination would compromise subject 's health likely result nonconformance protocol . 6 . History congenital abdominal disorder , intussusception , abdominal surgery . 7 . Known suspected impairment immunological function base medical history physical examination . 8 . Household contact immunosuppressed individual pregnant woman . 9 . Prior receipt intent receive rotavirus / diphtheria , tetanus , pertussis , Haemophilus Influenzae type b , Hepatitis B vaccine ( birth dose ) inactivate polio vaccine ( IPV ) study period outside study . OPV dose receive national / subnational immunization day allow . 10 . A known sensitivity allergy component study vaccine . 11 . Clinically detectable congenital genetic defect . 12 . History persistent diarrhea ( define diarrhea last 14 day longer ) . 13 . Receipt immunoglobulin therapy / blood product since birth plan administration study period . 14 . History chronic administration ( defined 14 day ) immunosuppressant include corticosteroid . Infants inhale topical steroid may permit participate study . 15 . History neurologic disorder seizure . 16 . Any medical condition parent / infant , judgment Investigator , would interfere serf contraindication protocol adherence participant 's parent ' ability give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>8 Weeks</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>BRV-PV</keyword>
	<keyword>Rotavirus vaccine</keyword>
	<keyword>lot-to-lot consistency</keyword>
	<keyword>interference routine immunization</keyword>
</DOC>